It was written in the protocols for the COBRA trials and agreed to by CU6 with the FDA. They agreed that the results would conform to the existing SOC which was determined by the existing treatments. Any lesions which Clarity found which were not seen in the imaging of Illucix etc were deemed to be false positives. Now things may have changed since then, redesigned studies, etc., of which I'm not aware, but these are facts and I'm surprised that people on here are unaware of it. I'm hoping that someone with some knowledge can shed some light on current studies because if there's been no changes made to these protocols this might explain the current sp. It basically means the current revenue produces control the market.
CU6 Price at posting:
$2.83 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)